Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

<ul><li>Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.</li><li>The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests.</li><li>We remain optimistic about Amgen’s future growth and maintain our 'Hold' rating on the stock with a revised target price.</li></ul>

Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings.The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests.We remain optimistic about Amgen’s future growth and maintain our 'Hold' rating on the stock with a revised target price.

Stock Market News, Outlooks, and Top Picks, Cappuccino Finance

Cappuccino Finance

Stock Market News, Outlooks, and Top Picks

Cappuccino Finance, provides Financial vignettes for your cappuccino break!

Fun & informational articles to read in 10 min or less.

Equity Bottom-Up

<ul><li>It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildly</li><li>Healthcare companies provide essential services regardless of economic conditions.</li><li>The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!</li></ul>

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to fluctuate wildlyHealthcare companies provide essential services regardless of economic conditions.The screener results were quite satisfactory. AbbVie, Amgen, and Merck. I like all of them!

Dividend HealthCare Stocks Screener – Jan 2022

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>The short-term bullish reversal discussed last week is officially underway now that the S&amp;P 500 has reclaimed its 200-day MA, but we are not yet out of the woods.</li>
<li>We discuss what we are watching to determine whether this is just an oversold bounce that resolves lower, or if the S&amp;P 500 is headed back to all-time highs.</li>
<li>The prior two trading days appears to be the start of a short-term mean reversion, where beaten down growth areas (ARKK, software, biotech, etc.) are outperforming.</li>
</ul>


The short-term bullish reversal discussed last week is officially underway now that the S&amp;P 500 has reclaimed its 200-day MA, but we are not yet out of the woods.
We discuss what we are watching to determine whether this is just an oversold bounce that resolves lower, or if the S&amp;P 500 is headed back to all-time highs.
The prior two trading days appears to be the start of a short-term mean reversion, where beaten down growth areas (ARKK, software, biotech, etc.) are outperforming.


Not Out Of The Woods; SPX Back Above The 200-Day MA; Growth Catching A Bid; Buying Energy, Biotech

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

In technical publications like patents and research papers, cross-references are made to existing patents and research papers. We believe these mentions and citations can provide valuable insights into the views and impressions of experts in the specific innovations and technologies within a sector and hence the likelihood of success. In this report (which is the first one we are publishing) we have crawled through more than ten years of publications (several thousand) to analyze a subset in the Lifesciences space namely PEPTIDES.  Needless to say the same can be done with respect to other technological areas in other sectors as well.We backtested our methodology (dating three years back) to look for any specific actionable idea the analysis might throw up. We noted that among the small or mid-cap stocks that screened well half were acquired over the next three years Specific to this report we highlight over ten companies that are likely acquisition targets over the next three years. Within those, two companies that screen very well based purely on data mined from the publications and our parameters of number of innovations, number of citations, Recency, and Impact are a Germany based Nasdaq listed - Immatics (IMTX) and US-based Coherus (CHRS)

In technical publications like patents and research papers, cross-references are made to existing patents and research papers. We believe these mentions and citations can provide valuable insights into the views and impressions of experts in the specific innovations and technologies within a sector and hence the likelihood of success. In this report (which is the first one we are publishing) we have crawled through more than ten years of publications (several thousand) to analyze a subset in the Lifesciences space namely PEPTIDES.  Needless to say the same can be done with respect to other technological areas in other sectors as well.We backtested our methodology (dating three years back) to look for any specific actionable idea the analysis might throw up. We noted that among the small or mid-cap stocks that screened well half were acquired over the next three years Specific to this report we highlight over ten companies that are likely acquisition targets over the next three years. Within those, two companies that screen very well based purely on data mined from the publications and our parameters of number of innovations, number of citations, Recency, and Impact are a Germany based Nasdaq listed - Immatics (IMTX) and US-based Coherus (CHRS)

Stock Ideas Based on Data Mined from Technical Publications - A Look Into Peptides

<ul>
<li>Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings.</li>
<li>The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter.</li>
<li>Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing a strong correction.</li>
</ul>


Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for its offerings.
The company’s total revenue grew by 5% in Q2 compared to the previous year and 11% compared to the previous quarter.
Sadly, a trimmed guidance for the rest of 2021 resulted in the stock price witnessing a strong correction.


United States

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amgen Inc (AMGN US)

Amgen Inc.: Financial & Price Forecasts

Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their...

Baptista Research

Dividend HealthCare Stocks Screener – Jan 2022

It’s a volatile market these days! The Omicron variant, interest rate hikes, supply chain disruption, and labor shortage are causing the market to...

Cappuccino Finance

Not Out Of The Woods; SPX Back Above The 200-Day MA; Growth Catching A Bid; Buying Energy, Biotech

The short-term bullish reversal that we referenced last week is officially underway now that the S&P 500 has reclaimed its 200-day MA, but we are...

Vermilion Research

Stock Ideas Based on Data Mined from Technical Publications - A Look Into Peptides

We have screened for stock ideas in the area of PEPTIDES by datamining citations by industry experts in thousands of technical publications over...

Pyari Menon

Amgen Inc. - Investment Thesis

Amgen continued to witness a decent top-line growth despite the lingering effects of the pandemic driven by the gradually increasing demand for...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)